SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Space Exploration Technologies Corp., doing business as SpaceX, operates as an aerospace manufacturer, launch service provider, and satellite communications company. It is building the integrated hardware and software infrastructure of the future across space, connectivity, and AI. The firm designs, manufactures, launches, and operates products and services built on cutting-edge technologies, including the rockets and spacecraft. The company was founded by Elon Reeve Musk in 2002 and is headquartered in Starbase, TX.

Space Exploration Technologies Corp. - Ordinary Shares - Class A

SpaceX

SpaceXs stronger-than-expected quarterly results and rapid growth in its AI-compute business, alongside plans for an aggressive expansion, fueled a bullish reaction and a sharp after-hours move. Traders are divided over whether the growth outlook justifies the valuation given heavy capital spending, while some also point to a potential Tesla merger as an additional, uncertain catalyst.

Super Micro Computer, Inc. engages in the distribution and manufacture of information technology solutions and other computer products. Its products include twin solutions, MP servers, GPU and coprocessor, MicroCloud, AMD solutions, power supplies, SuperServer, storage, motherboards, chassis, super workstations, accessories, SuperRack and server management products. The company was founded by Charles Liang, Yih-Shyan Liaw, Sara Liu, and Chiu-Chu Liu Liang in September 1993 and is headquartered in San Jose, CA.

Super Micro Computer Inc

Super Micros preliminary quarterly update sharply raised its sales outlook and gross-margin expectations on stronger AI-platform demand, driving a rally and renewed optimism about AI-server growth. Traders largely welcomed the update and debated potential short covering and the stocks valuation, while some remained cautious about whether the gains will hold and whether execution can be sustained.

Netflix, Inc. engages in providing entertainment services. It also offers activities for leisure time, entertainment video, video gaming, and other sources of entertainment. It operates through the United States and International geographic segments. The company was founded by Marc Randolph and Wilmot Reed Hastings on August 29, 1997 and is headquartered in Los Gatos, CA.

Netflix Inc.

Netflix Inc

Netflix shares came under pressure after its earnings report paired a profit beat with a weaker fourth-quarter outlook and a lower advertising-revenue forecast. Traders focused on slowing growth and streaming competition, while some dip buyers argued the selloff was excessive given the companys continued profitability.

Zebec's integrated products - real time payroll apps, on-chain payments infrastructure and networked DePIN - serve companies of all sizes, merchants and individuals and help transcend the boundaries of traditional banking and diminish the role of financial intermediaries.

Zebec Network

ZBCN is drawing attention on a sharp price rebound and a renewed breakout attempt, with traders linking the move to Robinhood Chain and other payroll/payment partnerships. Bullish posts point to expanding adoption, while skeptics say sustained usage, trading volume and token demand still need to confirm the thesis; the Robinhood-related catalyst is also discussed with some uncertainty.

Rocket Lab Corp. engages in the development of rocket launch and control systems for the space and defense industries. It operates through the Launch Services and Space Systems segments. The Launch Services segment provides launch services to customers on a dedicated mission or ride-share basis. The Space Systems segment consists of spacecraft engineering and design services, spacecraft components, spacecraft manufacturing, and on-orbit mission operations. The company was founded by Peter Beck in 2006 and is headquartered in Long Beach, CA.

Rocket Lab Corp.

Rocket Lab USA Inc

Rocket Labs Neutron first flight has been pushed to 2027 after a manufacturing defect in its carbon-composite propellant dome, with replacement work underway. Traders remain divided: some question execution and the lack of a firmer schedule, while others view the selloff as an overreaction and are buying for the long term.

Northrop Grumman Corp. engages in the provision of advanced aircraft systems. It operates through the following segments: Aeronautics Systems, Defense Systems, Mission Systems, and Space Systems. The Aeronautics Systems segment is involved in the design, development, production, integration, sustainment, and modernization of advanced aircraft systems for the U.S. Air Force, the U.S. Navy, other U.S. government agencies, and international customers. The Defense Systems segment includes integrated battle management systems, weapons systems and aircraft, and mission systems sustainment and modernization. The Mission Systems segment offers advanced mission solutions and multifunction systems, primarily for the U.S. defense and intelligence community, and international customers. The Space Systems segment delivers end-to-end mission solutions through the design, development, integration, production and operation of space, missile defense, launch and strategic missile systems for national security, civil government, commercial, and international customers. The company was founded by John K. Northrop, Thomas V. Jones, and Kent Kresa in 1939 and is headquartered in Falls Church, VA.

Northrop Grumman Corp.

Northrop Grummans quarterly results beat expectations, its 2026 outlook was raised, and its backlog reached a record, driving the sharp move higher. Traders are weighing the strong results against a pullback from the session high and whether buyers can sustain the gains.

TG Therapeutics, Inc. engages in the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its product pipeline includes TG-1501, TG-1701, Ublituximab, and Umbralisib. The company was founded by Michael Sean Weiss and Laurence H. Shaw on May 18, 1993 and is headquartered in Morrisville, NC.

TG Therapeutics Inc

Attention is centered on TG Therapeutics MSToronto presentations, especially initial Phase 1 azer-cel data in progressive MS, alongside long-term BRIUMVI and other clinical updates. Traders are positioning ahead of the readouts, with some optimistic about azer-cels potential and others stressing that its clinical impact remains uncertain; ongoing BRIUMVI growth provides a commercial backdrop.

NuScale Power Corp. provides proprietary and innovative advanced small modular reactor (SMR) nuclear technology, with a mission to help power the global energy transition by delivering safe, scalable, and reliable carbon-free energy. Its products include VOYGR SMR Plants and Energy Exploration (E2) Centers. The company was founded by José N. Reyes in 2007 and is headquartered in Corvallis, OR.

NuScale Power Corporation - Ordinary Shares - Class A

NuScale Power Corp

NuScale is under pressure after Barclays downgraded the stock, citing commercial execution risks and delays in securing a definitive TVAENTRA1 agreement for the proposed deployment. Traders debate whether the selloff overstates the risk: bears point to the lack of firm project commitments, while bulls cite AI-driven power demand and NuScales longer-term nuclear opportunity.

International Business Machines Corp. is an information technology company, which engages in the provision of integrated solutions that leverage information technology and knowledge of business processes. It operates through the following segments: Software, Consulting, Infrastructure, Financing, and Other. The Software segment combines hybrid cloud platform and software solutions to help clients become more data-driven, and to automate, secure, and modernize their environments. The Consulting segment focuses on integrating skills on strategy, experience, technology and operations by domain and industry. The Infrastructure segment offers solutions for hybrid cloud and is the foundation of the hybrid cloud stack. Infrastructure is optimized for infusing AI into mission-critical transactions and tightly integrated with IBM Software including Red Hat for accelerated hybrid cloud benefits. The Financing segment refers to the client and commercial financing, facilitating IBM clients’ acquisition of IT systems, software, and services. The company was founded by Charles Ranlett Flint and Thomas J. Watson Sr. on June 16, 1911 and is headquartered in Armonk, NY.

International Business Machines Corp.

IBM is drawing attention ahead of its quarterly report, with traders focused on managements outlook and whether demand is improving after earlier weakness. Some see recent gains and bullish options activity as encouraging, while others worry the stock could fall again if results or guidance disappoint.

The Boeing Co. is an aerospace company, which engages in the manufacture of commercial jetliners and defense, space, and security systems. It operates through the following segments: Commercial Airplanes (BCA), Defense, Space and Security (BDS), and Global Services (BGS). The Commercial Airplanes segment includes the development, production, and market of commercial jet aircraft and provides fleet support services, principally to the commercial airline industry worldwide. The Defense, Space and Security segment refers to the research, development, production and modification of manned and unmanned military aircraft and weapons systems for global strike, including fighter and combat rotorcraft aircraft and missile systems, global mobility, including tanker, rotorcraft and tilt-rotor aircraft, and airborne surveillance and reconnaissance, including command and control, battle management and airborne anti-submarine aircraft. The Global Services segment provides services to commercial and defense customers. The company was founded by William Edward Boeing on July 15, 1916, and is headquartered in Arlington, VA.

Boeing Co.

Boeing Co

FAA certification of Boeings 737 MAX 10 is the dominant catalyst, with bulls viewing it as a step toward deliveries and cash generation while skeptics say approval alone may not move the stock. Traders largely focus on whether Boeing can ramp production and convert its backlog into actual deliveries.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Certara, Inc. (CERT) Q2 Earnings and Revenues Lag Estimates

Certara (CERT) delivered earnings and revenue surprises of -20.00% and -5.71%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

Strength Seen in Kymera Therapeutics (KYMR): Can Its 16.6% Jump Turn into More Strength?

Kymera Therapeutics (KYMR) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term.

Biotech Surges as Big Money Backs High-Stakes Kidney Disease Push

The immune system has become one of biotech's most important battlegrounds as drug developers race to target inflammatory pathways responsible for some of medicine's most difficult-to-treat diseases. Among the most closely watched areas is the complement system, a network of proteins that can trigger severe tissue damage when overactivated. With growing interest in kidney disorders and autoimmune diseases, investors are increasingly rewarding companies developing targeted therapies capable of interrupting these pathways with greater precision and fewer side effects.Shares of InflaRx N.V. ...

InflaRx N.V. (NASDAQ:IFRX) Short Interest Update

InflaRx N.V. (NASDAQ:IFRX - Get Free Report) was the recipient of a large decline in short interest in April. As of April 15th, there was short interest totaling 1,809,027 shares, a decline of 26.2% from the March 31st total of 2,452,174 shares. Approximately 3.0% of the company's stock are short...

InflaRx (IFRX) Expected to Announce Quarterly Earnings on Wednesday

InflaRx (NASDAQ:IFRX) will be releasing its Q1 2026 earnings before the market opens on Wednesday, May 6. (View Earnings Report at https://www.marketbeat.com/earnings/reports/2026-5-6-inflarx-stock...

InflaRx (NASDAQ:IFRX) Coverage Initiated at Oppenheimer

Oppenheimer initiated coverage on InflaRx in a report on Friday. They set an "outperform" rating and a $5.00 price target on the stock...

InflaRx's (IFRX) "Buy" Rating Reaffirmed at Guggenheim

Guggenheim reiterated a "buy" rating and set a $14.00 price target on shares of InflaRx in a report on Tuesday...

InflaRx N.V. (NASDAQ:IFRX) Receives Consensus Recommendation of "Moderate Buy" from Brokerages

InflaRx N.V. (NASDAQ:IFRX - Get Free Report) has been assigned an average recommendation of "Moderate Buy" from the seven analysts that are covering the company, Marketbeat reports. One analyst has rated the stock with a sell rating, one has issued a hold rating and five have issued a buy ratin...

InflaRx (NASDAQ:IFRX) Stock Price Up 32.5% - Should You Buy?

InflaRx (NASDAQ:IFRX) Stock Price Up 32.5% - Still a Buy...

InflaRx NV is a clinical-stage biopharmaceutical company, which engages in the discovery and development of inhibitors of the complement activation factor known as C5a and its receptor C5aR. Its primary product candidate is Vilobelimab. The company was founded by Niels Christoph Riedemann, Renfeng Guo, and Nicolas Fulpius in December 2007 and is headquartered in Jena, Germany.

InflaRx N.V.

IFRX Stock Soars Pre-Market After Experimental Drug Shows Promise In Treating Chronic Skin Diseases

Equity

Bullish Sentiment

<ul class="summary-bullets"><li>The mid-stage study aimed to evaluate the safety and pharmacokinetic/pharmacodynamic profile of INF904.</li><li>Over four weeks of therapy in patients with HS, the company observed rapid and clinically meaningful reductions in inflammatory signs and substantial reductions in patient-reported pain scores in the study.&nbsp;</li><li>No safety concerns were identified in either of the two patient categories, the company said. &nbsp;</li></ul>InflaRx N.V. (IFRX) announced on Monday that data from a mid-stage trial of its INF904 in certain skin conditions demonstrated positive outcomes, including a reduction in disease severity and pain, which sent shares rallying 62% in the pre-market session.The company <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.inflarx.de/Home/Investors/Press-Releases/11-2025-InflaRx-Reports-Positive-Phase-2a-Data-for-INF904-in-Hidradenitis-Suppurative--HS--and-Chronic-Spontaneous-Urticaria--CSU-.html">studied</a> the experimental drug in Hidradenitis Suppurative (HS) and Chronic Spontaneous Urticaria (CSU). It was aimed at evaluating the safety and pharmacokinetics / pharmacodynamics profile of INF904.While Hidradenitis suppurativa (HS) is a chronic skin disease that causes painful, boil-like lumps to form under the skin, Chronic spontaneous urticaria (CSU) is a skin condition characterized by recurrent, itchy hives (wheals) and/or swelling (angioedema) that lasts for six weeks or longer.The company said that the data provide a strong rationale for further development of the drug in both these diseases. &nbsp;<h2 class="st-heading-2">Mid-Stage Trial Results</h2>Over four weeks of therapy in patients with HS, the company observed rapid and clinically meaningful reductions in inflammatory signs and substantial reductions in patient-reported pain scores in the study.&nbsp;In CSU, the company observed substantial reductions in the 7-day Urticaria Activity Score (UAS7) broadly across patients, particularly among those with severe disease. Urticaria Activity Score (UAS) is a patient-reported tool used to measure the severity of chronic hives (urticaria) by assessing the number of hives and the intensity of itch daily.No safety concerns were identified in either of the two patient categories, the company said.The company is now looking forward to initiating a Phase 2b trial in HS in 2026, while also engaging in dialogue with possible collaborators to advance the drug in CSU.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/IFRX">IFRX stock</a> remained within the ‘extremely bullish’ territory over the past 24 hours, while message volume remained at ‘extremely high’ levels.IFRX stock is down 50% this year and by about 20% over the past 12 months.&nbsp;Also See: <a href="https://stocktwits.com/news-articles/markets/equity/grab-holdings-to-take-equity-interest-in-remote-driving-tech-startup/cLPcKrSRE2c">Grab Deepens Autonomous Mobility Push With $60 Million Investment In Vay</a>For updates and corrections, email newsroom[at]stocktwits[dot]com

Rising stock market chart on a trading board background.

The company said that the data provide a strong rationale for further development of the drug in Hidradenitis Suppurative and Chronic Spontaneous Urticaria.

Hold rates steady

Cut 25 bps

Hike 25 bps

Fed decision day is here - Kevin Warsh chairs his first FOMC meeting with markets pricing a hold at 3.50%-3.75% but watching for a hawkish shift. Vote on what you expect to be decided today, then drop your prediction for the first rate cut or hike in the comments.

What do you expect the Fed to decide at its FOMC meeting today? 
 
Drop a comment with when you expect the first cut/hike to be.

Current Price	$1.54
Prev Close	$1.45
Open	$1.45
Dividend Yield	0.00%
50-Day Moving Average	$1.94
Beta	1.21
Avg. Volume	500,452.27
PE Ratio	-1.47

52-Week High	$2.95
52-Week Low	$0.7984
Market Capitalization	$213.68M
EPS (Annual)	-$0.7654
Price to Book	1.36
Revenue Per Employee	$509.26

Feed

News

Sentiment

Earnings

Fundamentals

Info

IFRX Fundamentals